Compound Pipeline Depth (CPD)
The future of the catalogue. A deep pipeline keeps both the marketed face and the black programs supplied.
Formula
Thresholds & Bands
| Band | Range | State |
|---|---|---|
| Deep | ≥ 30 | ok |
| Thin | 15-30 | warn |
| Stalled | < 15 | crit |
Why This Metric Matters
Compound Pipeline Depth measures the total number of distinct chemical and biological compounds currently in active development across all stages — from early discovery through preclinical testing, clinical trials, and pre-manufacturing validation. The pipeline is the Directorate's future: every compound currently in production was once a pipeline entry, and the marketed products and black-program agents that sustain the Directorate's operations five years from now are pipeline entries today. A deep pipeline provides resilience against the inevitable attrition of development — most compounds fail before reaching production — while ensuring that both the public-facing pharmaceutical catalogue and the classified programs maintain a steady flow of new capabilities.
Threshold Justification
The 30-compound "Deep" threshold was derived from the Directorate's historical attrition analysis: given the observed stage-gate failure rate across discovery, preclinical, and clinical phases, a pipeline of 30 or more active compounds is required to yield the 4-6 new production-ready agents per cycle that the Directorate's strategic plan demands. Below 15 compounds, the probability of delivering even one new agent in the next two cycles falls below 50%, which the R&D division classifies as a "Stalled" pipeline — a condition that triggers emergency research-prioritization protocols and potential external acquisition of late-stage candidates.
Historical Context
CPD has been tracked per cycle since the Pharmacology division's formal reorganization in Q1 2024. The pipeline started at 22 compounds inherited from pre-PANOPTICON research programs, many of which were subsequently deprioritized or terminated during a portfolio rationalization in Q2 2024. Aggressive recruitment of research staff and the commissioning of two new discovery laboratories in late 2024 expanded the pipeline to 34 compounds by year-end. The metric has since fluctuated between 28 and 38 as compounds progress through development stages, with natural attrition offset by new discovery entries.
Collection Method
CPD is assessed per cycle by the R&D Pharmacology division's portfolio-management system. Each compound in the active development registry is counted once, regardless of development stage, provided it has an assigned project team, an active budget allocation, and has not been formally terminated or placed on indefinite hold. Compounds that have received production approval and transferred to Manufacturing are removed from the pipeline count. The per-cycle figure is published to the Synaptic Data Fabric alongside a stage-distribution breakdown (discovery, preclinical, Phase I/II/III, pre-manufacturing) that provides additional context for the headline number.
Known Failure Modes
The most significant distortion is "zombie compounds" — entries that remain in the active registry with nominal budget allocations and assigned teams but have made no meaningful development progress, inflating the pipeline count without contributing to future output. Dual-use compounds counted once in CPD may serve both public-catalogue and classified programs, meaning the apparent depth overstates the diversification of the pipeline across the Directorate's distinct needs. Additionally, early-stage discovery entries have a fundamentally different probability of reaching production than late-stage clinical candidates, and the flat count treats them as equivalent, potentially masking a pipeline that is deep in speculative early entries but thin in near-term deliverables.